论文部分内容阅读
目的；观察单用干扰素（安达芬）和泛昔洛韦、干扰素（安达芬）联合治疗慢性乙型肝炎的疗效。方法：４２例为泛昔洛韦联合干扰素组泛昔洛韦２５０ｍｇ，３次／日，共４个月，干扰素３００万ＩＵ１支肌注，隔日 １次，共４个月。３５例为单用干扰素剂量、方法、疗程同上。每一病例均有治疗前中后系列血清标本ＨＢｅＡｇ、ＨＢＶ－ＤＮＡ。结果：两组治疗后ＨＢｅＡｇ和ＨＢＶ－ＤＮＡ阴转率近期疗效分别为治疗组３０例（７１．４％）、２８（６６．６％）及３５例（８３％）例（７３．８％），而对照组为１４（４０．０％），１２例（３４．２％）及１５例（４２．８％）．１１例（３１．４％）。Ｐ＜０．０５。结论：泛昔洛韦联合干扰素治疗慢性肝炎患者的抗病毒效果优于单用干扰素组。
Objective To observe the efficacy of interferon (Andalfon) combined with interferon (Andafen) alone and famciclovir in the treatment of chronic hepatitis B. Methods: Forty-two patients were treated with famciclovir plus interferon 250 mg once daily for 4 months. Interferon 3 million IU1 were intramuscularly injected once a day for 4 months. 35 cases of interferon dosage alone, methods, treatment ibid. Serum specimens HBeAg and HBV-DNA were collected before and after treatment in each case. Results: The short-term curative effect of HBeAg and HBV-DNA negative conversion rate were 30 cases (71.4%), 28 (66.6%) and 35 cases (83%) in treatment group Compared with 14 (40.0%), 12 (34.2%) and 15 (42.8%) controls. Eleven cases (31.4%). P <0.05. Conclusion: The antiviral effect of famciclovir combined with interferon in patients with chronic hepatitis is better than that of interferon alone.